Short answer
Part D covers Zepbound for sleep apnea; the Bridge adds a weight-management path.
CMS says obstructive sleep apnea is a Part D-eligible diagnosis for GLP-1 coverage, so Medicare Part D can cover Zepbound (tirzepatide) for moderate to severe obstructive sleep apnea. The Congressional Research Service says GLP-1 drugs used only for weight loss are excluded from standard Part D. CMS says the new GLP-1 Bridge, running July 1, 2026 through December 31, 2027, includes the Zepbound KwikPen among the weight-management drugs for eligible beneficiaries.
Start here
What you actually came to find out
Plain answers first. Sources stay below for checking details.
For sleep apnea?
CMS says obstructive sleep apnea is a Part D-eligible diagnosis.
For weight loss alone?
The CRS says Part D excludes weight-loss-only use.
Is it in the Bridge?
CMS says the Zepbound KwikPen is included in the Bridge.
What drug is it?
Zepbound is tirzepatide, the same drug as Mounjaro.
Sleep-apnea use
Covered
CMS says obstructive sleep apnea is a Part D-eligible diagnosis for GLP-1 coverage.
Source trail: CMS
Weight loss alone
Excluded
The CRS says Part D excludes GLP-1 drugs used only for weight loss.
Source trail: Congressional Research Service
The Bridge
KwikPen included
CMS says the Zepbound KwikPen is among the weight-management drugs in the Bridge.
Source trail: CMS
Same drug
Tirzepatide
Zepbound is tirzepatide, the same active drug as Mounjaro.
Source trail: Congressional Research Service
The real distinction is the reason for the prescription: Zepbound for sleep apnea goes through Part D, while weight management has its own Bridge pathway.
Neutral landscape
The shape of the question
The CMS Bridge form is the main source for the medical path because it lists obstructive sleep apnea as a Part D-eligible diagnosis.
Source trail: CMS
The weight-loss boundary still applies, and the CRS says weight-loss-only use is excluded.
Source trail: Congressional Research Service
The Bridge adds a path, since CMS includes the Zepbound KwikPen among the Bridge drugs.
Source trail: CMS
The drug identity helps, because Zepbound is tirzepatide, the same active ingredient as Mounjaro.
Source trail: Congressional Research Service
Curator core
What the authorities say
These sources are here for the reader who wants to check the work. The plain-English answer stays above them.
Source 01
CMS
Medicare GLP-1 Bridge Prior Authorization Form
The CMS Bridge prior authorization form lists the Part D-eligible diagnoses that route to a Part D plan and the body-mass-index and lifestyle conditions for the Bridge.
Source framing
CMS says diagnoses like type 2 diabetes, cardiovascular risk reduction, obstructive sleep apnea, and MASH route to the Part D plan, while the Bridge covers weight management with body-mass-index and lifestyle conditions.
Strongest for: which diagnoses go to Part D versus the Bridge, and the Bridge conditions
Read at CMSSource 02
Congressional Research Service
Medicare Coverage of GLP-1 Drugs
The Congressional Research Service summarizes Medicare coverage of GLP-1 drugs, including the statutory weight-loss exclusion and coverage for diabetes and cardiovascular indications.
Source framing
The Congressional Research Service says GLP-1 drugs are not covered under Part D when used for weight loss, but are covered for medically accepted indications such as type 2 diabetes and cardiovascular risk reduction.
Strongest for: the weight-loss exclusion and the covered medical indications
Read at Congressional Research ServicePlain-English forks
The forks people face
Most retirement questions hide a few smaller decisions. These are the practical pieces that change the plan.
Is it for sleep apnea or weight loss?
Why it matters: Sleep apnea goes through Part D; weight management has the Bridge.
In real life: This fork sets the pathway.
What to look at: What to look at: the CMS Bridge prior authorization form.
Do you meet the Bridge conditions?
Why it matters: The Bridge sets body-mass-index and health-condition criteria.
In real life: This fork decides Bridge eligibility.
What to look at: What to look at: the CMS Bridge form.
Which formulation is prescribed?
Why it matters: CMS names the Zepbound KwikPen specifically in the Bridge.
In real life: This fork can affect the Bridge path.
What to look at: What to look at: the formulation on your prescription.
Common questions
Quick answers
Short, plain answers for the questions people usually have next. The source trail stays available below.
Does Medicare cover Zepbound for sleep apnea?+
CMS says obstructive sleep apnea is a Part D-eligible diagnosis for GLP-1 coverage, so Part D can cover Zepbound for moderate to severe obstructive sleep apnea.
Does Medicare cover Zepbound for weight loss?+
The Congressional Research Service says GLP-1 drugs used only for weight loss are excluded from standard Part D, though the new Bridge adds a weight-management path.
Is Zepbound in the GLP-1 Bridge?+
CMS says the Zepbound KwikPen is among the weight-management drugs available through the GLP-1 Bridge from July 1, 2026 through December 31, 2027.
How is Zepbound different from Mounjaro?+
Both are tirzepatide, but Zepbound is approved for weight management and sleep apnea while Mounjaro is approved for type 2 diabetes.
Does the Bridge cover every Zepbound form?+
CMS names the Zepbound KwikPen specifically among the Bridge drugs, so the formulation matters.
How this page is curated
This page uses the CMS GLP-1 Bridge prior authorization form and page and the Congressional Research Service summary. It separates the sleep-apnea indication from weight management because Medicare covers them through different pathways.
Read the planner methodologyTrust anchor
Sources used on this page
Every source named above is listed here in one place.
CMS. Medicare GLP-1 Bridge Prior Authorization Form
https://www.cms.gov/glp-1-bridge.pdfCongressional Research Service. Medicare Coverage of GLP-1 Drugs
https://www.congress.gov/crs-product/IF12758
Before you act on this
This plan is educational. It is not personalized financial, tax, or insurance advice. Projections illustrate the math, they do not predict the future. Talk to your own licensed financial professional before acting on any of it.